Follow-up to REDUCE study shows low rate of prostate cancer diagnosis
The four-year REDUCE (REduction by DUtasteride of prostate Cancer Events) clinical study evaluated prostate cancer risk reduction in men taking dutasteride, a 5-alpha-reductase inhibitor (5ARI) typically used to treat enlarged prostate. REDUCE results showed that dutasteride decreased the risk of biopsy detectable prostate cancer by 22.8 percent compared to a placebo group, but concerns remained about the drug's effectiveness. Results from a follow-up study are now published in The Journal of Urology.
"The REDUCE Follow-up Study was a two-year observational follow-up of men who participated in the four-year REDUCE trial," says lead investigator Robert L. Grubb III, Associate Professor of Surgery (Urology), Washington University of Medicine in St. Louis, Missouri. "The primary objective was to collect data on the occurrence of new cases of prostate cancer for two years beyond REDUCE."
Nearly 2,800 men from the REDUCE study participated, representing extension safety and at-risk populations. In the original study, about half were treated with dutasteride and the remainder received a placebo.
Shortly after the REDUCE study's conclusion, Dr. Grubb and co-investigators followed participants with a clinic visit. They also conducted up to two annual telephone calls, collecting patient data on prostate cancer events, chronic medication use, prostate specific antigen levels, and serious adverse events. No drugs were administered and no additional biopsies were performed except those "for-cause" when clinically indicated.
Results showed that few new prostate cancers were detected during the two-year follow-up in either treatment group and no deaths were reported. However, the former dutasteride group produced double the number of cancers than the former placebo group (14 vs. 7). Investigators hypothesize that any prostate cancer that may have been suppressed by dutasteride during REDUCE was no longer being suppressed for those subjects who did not continue on 5ARI therapy. To some extent, observations during the follow-up study support this concept.
Using Gleason scores, the system used to evaluate the prognosis of prostate cancer, no high grade prostate cancers (Gleason Score 8-10) were detected. No new safety issues surfaced.
More men from the placebo group underwent biopsy (11.6 percent) than men from the dutasteride group (7.9 percent). A higher incidence of prostate cancer (1.3 percent) was observed in men in the dutasteride group who did not continue 5ARI treatment. Overall, men in either group who took a 5ARI during the follow-up study tended to have fewer cancers.
"Although this study provides real-world observational data for subjects who had been randomized to four years of dutasteride therapy, it has limitations," cautions Dr. Grubb. "Men in the at-risk population had a low risk of prostate cancer diagnosis due to several prior negative biopsies and corresponding conclusions are specific to the population studied. In addition, some men who dropped out of REDUCE early may have been off dutasteride treatment for longer than the two-year observational period."
The two years of additional study have been useful in demonstrating a low rate of new prostate cancer diagnoses among men from the REDUCE study.
More information: Grubb, R. et al. The REDUCE Follow-up Study: Low Rate of New Prostate Cancer Diagnoses Observed During a 2-year, Observational, Follow-up Study of Men Who Participated in the REDUCE Trial, The Journal of Urology, Volume 189, Issue 3 (March 2013). DOI: dx.doi.org/10.1016… .2012.09.099
Journal reference: Journal of Urology
Provided by Elsevier
- Commonly used drug for enlarged prostate slows growth of early-stage prostate cancer Jan 23, 2012 | not rated yet | 0
- Relationship between prostate information and lower urinary-tract symptoms evident Nov 13, 2008 | not rated yet | 0
- PSA test better predicts cancer in men taking prostate-shrinking drug Dec 16, 2010 | not rated yet | 0
- FDA links some prostate drugs to cancer risk Jun 09, 2011 | not rated yet | 0
- Doctors can now detect hard-to-diagnose prostate cancer Aug 09, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
How can there be a term called "intestinal metaplasia" of stomach
4 hours ago Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
Alcohol and acetaminophen
May 13, 2013 Edit: sorry for the typo in the title , can't edit I looked around on google quite a bit and it's very hard to find precise information on the...
- More from Physics Forums - Medical Sciences
More news stories
The surgical management of non-small cell lung cancer (NSCLC) in U.S. hospitals varies widely depending on the race of the patient, according to a new study.
Cancer 1 hour ago | not rated yet | 0
Treatment with an Alpha-1 proteinase inhibitor (A1-PI), a naturally occurring protein that protects lung tissue from breakdown and protects the lung's elasticity, is effective in slowing the progression of emphysema in patients ...
Cancer 1 hour ago | not rated yet | 0
Scientists from Nanyang Technological University (NTU) and Lund University, Sweden, have bioengineered a novel molecule which has been proven to successfully kill tumour cells.
Cancer 1 hour ago | 5 / 5 (1) | 0
An article published on the journal Nature describes the major role that Pyruvate dehydrogenase (PDH) —an enzyme of cellular energy metabolism— plays in the regulation of the cellular senescence induce ...
Cancer 2 hours ago | not rated yet | 0
(Medical Xpress)—Scientists at the School of Medicine have shown that their previously identified therapeutic approach to fight cancer via immune cells called macrophages also prompts the disease-fighting killer T cells ...
Cancer 3 hours ago | not rated yet | 0 |
Delayed transfer to the intensive care unit (ICU) in hospitalized patients significantly increases the risk of dying in the hospital, according to a new study from researchers in Chicago.
56 minutes ago | not rated yet | 0
In a remote fishing community in Venezuela, a lone fisherman sits on a cliff overlooking the southern Caribbean Sea. This man –– the lookout –– is responsible for directing his comrades on the water, ...
1 hour ago | not rated yet | 0 |
A novel approach to obstructing the runaway inflammatory response implicated in some types of asthma has shown promise in a Phase IIa clinical trial, according to U. S. researchers.
1 hour ago | not rated yet | 0
Authorities are investigating rice mills in southern China following tests that found almost half of the staple grain in one of the country's largest cities was contaminated with a toxic metal.
1 hour ago | 5 / 5 (1) | 0
Johns Hopkins researchers say they have discovered specific chemical alterations in two genes that, when present during pregnancy, reliably predict whether a woman will develop postpartum depression.
6 hours ago | not rated yet | 0 |